HER2 (human epidermal growth factor receptor 2)-targeted therapy in breast cancer is one of the earliest and arguably most successful examples of the modern class of targeted drugs. Initially identified in the 1980s, the observation that HER2 acts as an independent predictor of poor prognosis in the 20% of breast cancer cases carrying a gene amplification or protein overexpression cemented its place at the forefront of research in this field. The outlook for patients with HER2-positive breast cancer has been revolutionized by the introduction of HER2-targeted agents, such as trastuzumab and lapatinib, yet resistance is frequently encountered and multiple different resistance mechanisms have been identified. We have explored resistance to a novel pan-HER inhibitor, AZD8931, and we examine mechanisms of resistance common to trastuzumab, lapatinib and AZD8931, and discuss the current problems associated with translating the wealth of pre-clinical data into clinical benefit.
Skip Nav Destination
Article navigation
August 2014
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
Conference Article|
August 11 2014
Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer
Helen Creedon;
Helen Creedon
*Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR
Search for other works by this author on:
Adam Byron;
Adam Byron
*Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR
Search for other works by this author on:
Joanna Main;
Joanna Main
*Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR
Search for other works by this author on:
Larry Hayward;
Larry Hayward
*Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR
Search for other works by this author on:
Teresa Klinowska;
Teresa Klinowska
†Oncology iMed, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, U.K.
Search for other works by this author on:
Valerie G. Brunton
Valerie G. Brunton
1
*Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR
1To whom correspondence should be addressed (emailv.brunton@ed.ac.uk).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
April 23 2014
Online ISSN: 1470-8752
Print ISSN: 0300-5127
© The Authors Journal compilation © 2014 Biochemical Society
2014
Biochem Soc Trans (2014) 42 (4): 822–830.
Article history
Received:
April 23 2014
Citation
Helen Creedon, Adam Byron, Joanna Main, Larry Hayward, Teresa Klinowska, Valerie G. Brunton; Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer. Biochem Soc Trans 1 August 2014; 42 (4): 822–830. doi: https://doi.org/10.1042/BST20140109
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.